✉ Email this page to a colleague
« Back to Dashboard
GTx-024 is an investigational drug.
There have been 35 clinical trials for GTx-024. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are GTx, Columbia University, and National Cancer Institute (NCI).
Recent Clinical Trials for GTx-024
|Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects||Acasti Pharma Inc.||Phase 1|
|Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects||Acasti Pharma Inc.||Phase 1|
|Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects||Acasti Pharma Inc.||Phase 1|